|
Collaboration Agreement - Additional Information (Detail) (USD $)
|
3 Months Ended |
|
|
|
Mar. 31, 2015
|
Dec. 31, 2014
|
Apr. 24, 2015
|
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |
|
|
|
| Amounts receivable |
$ 1,559,000us-gaap_AccountsReceivableNetCurrent
|
$ 5,676,000us-gaap_AccountsReceivableNetCurrent
|
|
| Subsequent Event |
|
|
|
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |
|
|
|
| Proceeds From Advance reimbursement research and development |
|
|
27,000,000us-gaap_RelatedPartyTransactionDueFromToRelatedParty
/ us-gaap_SubsequentEventTypeAxis
= us-gaap_SubsequentEventMember
|
| Hold-back and third-party expense |
|
|
3,800,000ogxi_TransactionFromRelatedPartyHoldAmountWithOtherExpensesIncurredWithRelatedParty
/ us-gaap_SubsequentEventTypeAxis
= us-gaap_SubsequentEventMember
|
| Subsequent Event | Collaborative Arrangement |
|
|
|
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |
|
|
|
| Hold-back and third-party expense |
|
|
3,000,000ogxi_TransactionFromRelatedPartyHoldAmountWithOtherExpensesIncurredWithRelatedParty
/ us-gaap_SubsequentEventTypeAxis
= us-gaap_SubsequentEventMember
/ us-gaap_TypeOfArrangementAxis
= us-gaap_CollaborativeArrangementMember
|
| Teva Pharmaceutical Industries Ltd. [Member] |
|
|
|
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |
|
|
|
| Maximum cost exposure if third-party agreements discovered after the termination date |
100,000ogxi_RelatedPartyTransactionAmountsOfPossibleMaximumCostExposureSubsequentToTerminationOfCollaborationAgreement
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= ogxi_TevaPharmaceuticalIndustriesMember
|
|
|
| Receivables for unbilled expense reimbursement |
1,400,000ogxi_ReceivablesForUnbilledExpenseReimbursement
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= ogxi_TevaPharmaceuticalIndustriesMember
|
|
|
| Amounts receivable |
1,600,000us-gaap_AccountsReceivableNetCurrent
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= ogxi_TevaPharmaceuticalIndustriesMember
|
|
|
| Teva Pharmaceutical Industries Ltd. [Member] | Collaborative Arrangement |
|
|
|
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |
|
|
|
| Direct and indirect costs incurred |
30,000,000ogxi_DirectAndIndirectCostsIncurred
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= ogxi_TevaPharmaceuticalIndustriesMember
/ us-gaap_TypeOfArrangementAxis
= us-gaap_CollaborativeArrangementMember
|
|
|
| Isis Pharmaceuticals, Inc. [Member] | Collaborative Arrangement | Maximum |
|
|
|
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |
|
|
|
| Percentage of milestone payments required to be paid to third party |
30.00%ogxi_PercentageOfMilestonePaymentsRequiredToBePaidToThirdParty
/ us-gaap_RangeAxis
= us-gaap_MaximumMember
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= ogxi_IsisPharmaceuticalsMember
/ us-gaap_TypeOfArrangementAxis
= us-gaap_CollaborativeArrangementMember
|
|
|
| Isis Pharmaceuticals Inc. and University of British Columbia [Member] |
|
|
|
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |
|
|
|
| Milestone payment due |
20,000,000ogxi_MilestonePaymentDue
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= ogxi_IsisPharmaceuticalsIncAndUniversityOfBritishColumbiaMember
|
|
|
| Period of milestone payment |
21 days
|
|
|
| Reserve for contingency of non payment of non-royalty milestone amount |
20,000,000ogxi_ReserveForContingencyOfNonPaymentOfNonRoyaltyMilestoneAmount
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= ogxi_IsisPharmaceuticalsIncAndUniversityOfBritishColumbiaMember
|
|
|
| Milestone payment made |
10,000,000ogxi_MilestonePaymentMade
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= ogxi_IsisPharmaceuticalsIncAndUniversityOfBritishColumbiaMember
|
|
|
| Balance amount of milestone payment |
10,000,000ogxi_BalanceAmountOfMilestonePayment
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= ogxi_IsisPharmaceuticalsIncAndUniversityOfBritishColumbiaMember
|
|
|
| Balance in advanced reimbursement of development activities |
$ 30,000,000ogxi_BalanceInAdvancedReimbursementOfDevelopmentActivities
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= ogxi_IsisPharmaceuticalsIncAndUniversityOfBritishColumbiaMember
|
|
|
| Isis Pharmaceuticals Inc. and University of British Columbia [Member] | Collaborative Arrangement | Maximum |
|
|
|
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |
|
|
|
| Percentage of net sales required to be paid as royalty to third party |
8.00%ogxi_PercentageOfNetSalesRequiredToBePaidAsRoyaltyToThirdParty
/ us-gaap_RangeAxis
= us-gaap_MaximumMember
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= ogxi_IsisPharmaceuticalsIncAndUniversityOfBritishColumbiaMember
/ us-gaap_TypeOfArrangementAxis
= us-gaap_CollaborativeArrangementMember
|
|
|
| Isis Pharmaceuticals Inc. and University of British Columbia [Member] | Collaborative Arrangement | Minimum [Member] |
|
|
|
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |
|
|
|
| Percentage of net sales required to be paid as royalty to third party |
4.00%ogxi_PercentageOfNetSalesRequiredToBePaidAsRoyaltyToThirdParty
/ us-gaap_RangeAxis
= us-gaap_MinimumMember
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= ogxi_IsisPharmaceuticalsIncAndUniversityOfBritishColumbiaMember
/ us-gaap_TypeOfArrangementAxis
= us-gaap_CollaborativeArrangementMember
|
|
|